Evolus is trying to reduce its reliance on a single flagship wrinkle-treatment by pushing into more countries and rolling out new products that could broaden its customer base. The big question is whether demand for cosmetic procedures rebounds soon enough—and whether newer launches turn into steady repeat sales rather than a short-lived early spike.Read more
Catalysts About Evolus Evolus is a cash pay focused aesthetics company that markets neuromodulators and hyaluronic acid fillers to physicians and consumers. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Evolus Evolus is a performance beauty company focused on cash pay injectable aesthetics, including neurotoxin and hyaluronic acid filler products. What are the underlying business or industry changes driving this perspective?Read more
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
